Produção Nacional
Revisado por pares
New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape
2014; Taylor & Francis; Volume: 25; Issue: 3 Linguagem: Inglês
10.1517/13543776.2014.993969
ISSN1744-7674
AutoresAlice Machado-Silva, Pedro Pires Goulart Guimarães, Carlos Alberto Pereira Tavares, Rubén D. Sinisterra,
Tópico(s)Research on Leishmaniasis Studies
ResumoIntroduction: Although leishmaniasis is estimated to cause the ninth largest disease burden among individual infectious diseases, it is still one of the most neglected diseases in terms of drug development. Current drugs are highly toxic, resistance is common and compliance of patients to treatment is low, as treatment is long and drug price is high.
Referência(s)